# BPC-157: Research Overview — Youth Lab Peptides > A literature summary of BPC-157, a synthetic gastric pentadecapeptide studied for tissue repair and angiogenesis in animal models. Covers mechanism, the human evidence base, reported effects, and cited safety cautions. A synthetic gastric pentadecapeptide studied for tissue repair and blood-vessel growth in animal models — with only three small human pilot studies to date. ## The short version BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a sequence found in human gastric juice. In animal studies it has been linked to faster healing of tendons, ligaments, muscle, and gut lining, largely through effects on **angiogenesis** — the growth of new blood vessels. The honest caveat sits right at the front: almost everything known about BPC-157 comes from rodent studies. As of 2025, a narrative review counted only three small human pilot studies, concluded that rigorous, large-scale human trials are lacking, and recommended treating BPC-157 as investigational [2]. A tiny first-in-human safety pilot in two adults found intravenous BPC-157 well tolerated with no measurable changes in standard safety bloodwork [1] — reassuring, but far too small to establish either safety or benefit at scale. This page describes what has actually been studied, in which species, and what the literature says people report — it does not recommend a dose or a use for any individual. ## What it is BPC-157 is a synthetic pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular formula C62H98N16O22) built from a partial sequence of a naturally occurring gastric-juice protein, BPC. It is also referenced in older literature under research designations including PL 14736, PLD-116, and PL-10. Unlike many peptides discussed in tissue-repair research, BPC-157 is notably stable — it resists breakdown by stomach acid and digestive enzymes far better than most peptides its size, which is part of why it was originally isolated from gastric juice and why it has been studied via oral, intramuscular, and intravenous routes. ## How it works BPC-157's best-characterized mechanism is pro-angiogenic: it up-regulates and promotes internalization of the VEGFR2 receptor, triggering downstream VEGFR2-Akt-eNOS (nitric-oxide) signaling that drives new blood-vessel formation and accelerates blood-flow recovery in ischemic tissue [4]. A second reported pathway involves the FAK-paxillin complex, which governs how cells migrate — relevant to wound closure and tissue remodeling. In cultured tendon fibroblasts, BPC-157 has also been shown to sensitize cells to growth-hormone-receptor signaling, one proposed explanation for its reported effects on tendon and ligament healing. Additional reported routes touch the nitric-oxide system and several neurotransmitter systems, though the angiogenic and cytoprotective pathways remain the most consistently replicated across studies. ## What the research shows *Human safety pilot.* In a first-in-human pilot, intravenous BPC-157 at doses up to 20 mg was administered to two healthy adults (a 58-year-old man and a 68-year-old woman). Both tolerated it well, with no adverse events and no measurable change in cardiac, hepatic, renal, thyroid, or glucose biomarkers [1]. This is reassuring but reflects an n of two, not an efficacy trial. *Pharmacokinetics.* The first formal PK/ADME characterization, conducted in rats and beagle dogs, found linear pharmacokinetics, a very short elimination half-life (under 30 minutes), modest intramuscular bioavailability (roughly 14-19% in rats, 45-51% in dogs), and rapid breakdown into small fragments that enter normal amino-acid metabolism [3]. *Angiogenesis.* Across chick chorioallantoic membrane assays, a rat hindlimb ischemia model, and human vascular endothelial cells, BPC-157 increased vessel density and accelerated blood-flow recovery after induced ischemia, an effect that was blocked when endocytosis was inhibited — supporting the VEGFR2-internalization mechanism directly [4]. *Foundational cytoprotection.* In Wistar rats, BPC-157 reduced gastric ulcer area and accelerated healing, with intramuscular delivery outperforming intragastric delivery and an ulcer-inhibition ratio of roughly 45.7-65.6% at higher doses [5]. *2025 narrative review.* Taken together, a 2025 review concluded that despite broad preclinical support, human data remain extremely limited — only three pilot studies — and that BPC-157 should be considered investigational pending rigorous, large-scale trials [2]. ## Reported effects, cautions & safety People using BPC-157 in research-use communities describe a fairly consistent cluster of experiences. **These reports are anecdotal, not clinical evidence** — they come from online forums, wellness-clinic testimonials, and narrative reviews quoting user reports, not from controlled human trials. *Reported benefits:* the most common reason people say they try BPC-157 is faster-feeling recovery from tendon, ligament, and joint injuries — old sprains or tennis-elbow-type pain reported as more usable within one to three weeks. Many also describe less day-to-day joint stiffness, improved digestive symptoms (less bloating, cramping, and urgency), a general sense of reduced inflammation, faster-looking skin or wound healing, and occasionally better sleep or steadier mood. *Reported adverse effects:* the most common complaint by far is a local injection-site reaction — brief stinging, redness, or a small bump that usually fades within a day. A minority report mild nausea or stomach upset, first-week fatigue, headache, dizziness (especially right after injecting), transient flushing or warmth, and, rarely, palpitations. *Cited cautions from the literature:* the central caution is simply that the human evidence is extremely thin — almost everything known comes from rodents, and as of 2025 only three small human pilot reports exist, with rigorous controlled trials still lacking [1][2]. A meaningful share of the foundational literature also comes from a single research group, limiting independent replication [2]. Because BPC-157's repair effects are tied to strong pro-angiogenic activity, there is a theoretical — not demonstrated — concern about its use in the context of active or suspected cancer, since tumors also depend on new blood-vessel growth [4]. Additional theoretical cautions include a possible interaction with serotonin-affecting medicines, unknown long-term effects of nudging growth-signaling pathways, a World Anti-Doping Agency ban in competitive sport, and an absence of any safety data in pregnancy, breastfeeding, or children. ## Where it fits in healthspan and cellular-aging research On this desk, BPC-157 represents the tissue-repair angle of aging research: the idea that faster, more complete healing of everyday wear — tendons, gut lining, minor wounds — is itself part of aging well. Its angiogenic mechanism connects loosely to [NAD+](/nad)'s role in cellular energy and repair capacity, though the two have not been studied together. Unlike [semaglutide](/semaglutide), which carries large controlled human trials, or [Thymosin Alpha-1](/thymosin-alpha-1), which has decades of international clinical use, BPC-157's promise currently rests almost entirely on animal data. See the [comparison page](/compare) for how its evidence base stacks up against the other three. ![BPC-157 research illustration — abstract angiogenic pathway motifs](/images/bpc-157.webp) --- Youth Lab Peptides is an independent, citation-anchored reading room on healthspan and cellular-aging research — not a clinic, not a supplier, and not a source of medical advice.